Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Phase III Safety, Efficacy, and Pharmacokinetic Study of NABI-IGIV 10% [Immune Globulin Intravenous (Human), 10%] in Subjects With Primary Immune Deficiency Disorders (PIDD)

NCT00538915 is registered in ClinicalTrials.gov with ADMA Biologics, Inc. as lead sponsor.

NCT NCT00538915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00538915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Phase III Safety, Efficacy, and Pharmacokinetic Study of NABI-IGIV 10% [Immune Globulin Intravenous (Human), 10%] in Subjects With Primary Immune Deficiency Disorders (PIDD)
Lead sponsor
ADMA Biologics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2007
Completion date
July 31, 2009
Enrollment
63 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune deficiency disorders (pidd)